Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-01 pm EDT 5-day change 1st Jan Change
73.46 USD +16.22% Intraday chart for Bio-Techne Corporation +15.65% -4.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged MT
Top Midday Gainers MT
US Equity Indexes Mixed as Investors Look for Clarity in Fed's Policy Path in Presidential Election Year MT
US Equity Indexes Mixed Ahead of Fed Policy Statement, Views on Monetary Policy Path for 2024 MT
Bio-Techne Shares Jump After Fiscal Q3 Beat MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82 MT
Transcript : Bio-Techne Corporation, Q3 2024 Earnings Call, May 01, 2024
Bio-Techne's Fiscal Q3 Adjusted Earnings Fall, Net Sales Rise MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q3 Revenue $303.4M MT
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024 CI
Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors CI
Bio-Techne to Enter Product Distribution Deal With Thermo Fisher Scientific MT
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79 MT
Bio-Techne Corporation Announces New Distribution Agreement with Thermo Fisher Scientific CI
Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay CI
Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe MT
Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85 MT
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating MT
Bio-Techne Positioned for Growth Amid Biotech Funding Recovery, UBS Says MT
Bio-Techne Says European Union IVDR Certification Received for Diagnostic Test Tracking Chronic Myeloid Leukemia MT
Transcript : Bio-Techne Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 09:45 AM
Transcript : Bio-Techne Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
North American Morning Briefing : Hopes of March -2- DJ
Stephens Adjusts Bio-Techne's Price Target to $87 From $70, Keeps Overweight Rating MT
Chart Bio-Techne Corporation
More charts
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
73.46 USD
Average target price
79.93 USD
Spread / Average Target
+8.81%
Consensus
  1. Stock Market
  2. Equities
  3. TECH Stock
  4. News Bio-Techne Corporation
  5. UBS Initiates Coverage on Bio-Techne With Buy Rating, $80 Price Target